Johnson & Johnson Gains 2.04% to $248.43, 7.12% Monthly Rally
Johnson & Johnson shares rose 2.04% to $248.43, outpacing the S&P 500 by 2.47% and gaining 7.12% over the past month as analysts forecast Q1 EPS of $2.68 on $23.43 billion revenue. The stock trades at a forward P/E of 21.1, above the industry average of 15.51.
1. Stock Performance
Johnson & Johnson closed at $248.43, marking a 2.04% increase from the previous session and outperforming the S&P 500's 0.43% decline; its shares have risen 7.12% over the past month, outpacing the medical sector's 1.34% loss.
2. Earnings Forecasts
Analysts project Q1 earnings per share of $2.68 on revenue of $23.43 billion, representing a 3.25% year-over-year EPS decline and a 7.04% revenue increase; full-year consensus estimates call for EPS of $11.54 and revenue of $100.29 billion, up 6.95% and 6.47%, respectively.
3. Valuation and Analyst Ratings
The stock is trading at a forward P/E of 21.1 versus the industry average of 15.51 and holds a PEG ratio of 2.36 above the industry’s 2.26; Johnson & Johnson carries a Zacks Rank of #3 (Hold), reflecting neutral analyst estimate revisions.